Dat	te:O	ct. 12, 2021			
Υοι	ur Name:	_Hao Chen			
Ma	Manuscript Title:Prognostic significance of postoperative longitudinal change of serum carcinoembryonic				
ant	tigen level in patients with	stage I lung adenocarcino	ma completely resected by single-port VATS: a retrospe	ctive	
stu	<u>dy</u>				
Ma	inuscript number (if know	າ):			
relator tor rela The	ated to the content of your rties whose interests may transparency and does no ationship/activity/interest e following questions appl unuscript only.	r manuscript. "Related" mobe affected by the content necessarily indicate a bias, it is preferable that you do to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>		
			e <u>defined broadly</u> . For example, if your manuscript perta		
to i me In i	the epidemiology of hyper dication, even if that med	tension, you should declar ication is not mentioned in upport for the work report	e all relationships with manufacturers of antihypertensi	ive	
to i me In i	the epidemiology of hyper dication, even if that med tem #1 below, report all s	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months.	e all relationships with manufacturers of antihypertensing the manuscript. ed in this manuscript without time limit. For all other it	ive	
to i me In i	the epidemiology of hyper dication, even if that med tem #1 below, report all s	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with	e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments	ive	
to i me In i	the epidemiology of hyper dication, even if that med tem #1 below, report all s	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with whom you have this	e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments (e.g., if payments were made to you or to your	ive	
to i me In i	the epidemiology of hyper dication, even if that med tem #1 below, report all s	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with	e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments	ive	
to i me In i	the epidemiology of hyper dication, even if that med tem #1 below, report all s	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments (e.g., if payments were made to you or to your institution)	ive	
to i me In i	the epidemiology of hyper dication, even if that med tem #1 below, report all s time frame for disclosure	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments (e.g., if payments were made to you or to your institution)	ive	
to i me In i	the epidemiology of hyperedication, even if that med tem #1 below, report all settime frame for disclosure	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments (e.g., if payments were made to you or to your institution)	ive	
to i me In i	All support for the present manuscript (e.g., funding,	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiXNone	e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments (e.g., if payments were made to you or to your institution)	ive	
to i me In i	All support for the present manuscript (e.g., funding, provision of study materials	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiXNone	e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments (e.g., if payments were made to you or to your institution)	ive	
to i me In i	All support for the present manuscript (e.g., funding, provision of study materials medical writing, article	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiXNone	e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments (e.g., if payments were made to you or to your institution)	ive	
to i me In i	All support for the present manuscript (e.g., funding, provision of study materials medical writing, article processing charges, etc.)	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiXNone	e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments (e.g., if payments were made to you or to your institution)	ive	
to i me In i	All support for the present manuscript (e.g., funding, provision of study materials medical writing, article	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiXNone	e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments (e.g., if payments were made to you or to your institution)	ive	
to i me In i	All support for the present manuscript (e.g., funding, provision of study materials medical writing, article processing charges, etc.)	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiXNone	e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments (e.g., if payments were made to you or to your institution)	ive	
to i me In i	All support for the present manuscript (e.g., funding, provision of study materials medical writing, article processing charges, etc.)	tension, you should declar ication is not mentioned in upport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiXNone	e all relationships with manufacturers of antihypertensing the manuscript. ed in this manuscript without time limit. For all other it Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	ive	

any entity (if not indicated

None

X__None

in item #1 above).

Consulting fees

Royalties or licenses

- 1		T	T
5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	•		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

I have no conflict of interests to declare.	
---	--

Please place an "X" next to the following statement to indicate your agreement:

Dat	e:Oc	t. 12, 2021			
	ır Name:				
	Nanuscript Title:Prognostic significance of postoperative longitudinal change of serum carcinoembryonic				
	entigen level in patients with stage I lung adenocarcinoma completely resected by single-port VATS: a retrospective				
stu	dy				
Ma	nuscript number (if known):			
rela par to t	ited to the content of your ties whose interests may b ransparency and does not	manuscript. "Related" me be affected by the content	I relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitmen . If you are in doubt about whether to list a o so.		
	following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>		
to t me	he epidemiology of hypert dication, even if that medi	tension, you should declare cation is not mentioned in apport for the work reporte	defined broadly. For example, if your manuscript perterally all relationships with manufacturers of antihypertens the manuscript. ed in this manuscript without time limit. For all other in	ive	
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as			
		needed) Time frame: Since the initia	I planning of the work		
	All support for the present	X None	in planning of the work		
	manuscript (e.g., funding,				
	provision of study materials,				
	medical writing, article				
	processing charges, etc.)				
	No time limit for this item.				
		Time frame: pas	t 36 months		
	Grants or contracts from	XNone			

any entity (if not indicated

None

X__None

in item #1 above).

Consulting fees

Royalties or licenses

		ı	
5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Please summarize the above conflict of interest in the following box	າ the following box:
--	----------------------

I have no conflict of interests to declare.		

Please place an "X" next to the following statement to indicate your agreement:

n -	0	-1 42 2024		
		ct. 12, 2021 _Keyi Jia		
			perative longitudinal change of serum carcinoembryonic	
		stage i lung adenocarcinon	na completely resected by single-port VATS: a retrospective	<u>'e</u>
	<u>udy</u> anuscript number (if know	n).		
	andscript number (ii know	··/·		
In ·	the interest of transparen	y we ask you to disclose al	I relationships/activities/interests listed below that are	
	•	-	ans any relation with for-profit or not-for-profit third	
	-		of the manuscript. Disclosure represents a commitment	
-	-	<u>-</u>	If you are in doubt about whether to list a	
	•	;, it is preferable that you do	•	
Th	e following questions appl	y to the author's relationsh	ips/activities/interests as they relate to the current	
ma	anuscript only.			
to	the epidemiology of hyper		defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.	
ln i	item #1 below, report all s	upport for the work reports	ed in this manuscript without time limit. For all other ite	ns.
	e time frame for disclosure		and the state of t	,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as needed)		
		Time frame: Since the initia	I planning of the work	
	All support for the present	X None	- Parinting of the Horit	
-	manuscript (e.g., funding,			

Time frame: past 36 months

_X__None

X__None

None

provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

Grants or contracts from

in item #1 above).

Royalties or licenses

Consulting fees

any entity (if not indicated

2

- 1		T	T
5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	•		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

I have no conflict of interests to declare.	
---	--

Please place an "X" next to the following statement to indicate your agreement:

Dat	re: Oc	t. 12. 2021		
	ır Name:			
			pperative longitudinal change of serum carcinoembryoni	<u></u> -
	-		ma completely resected by single-port VATS: a retrospe	
stu				
Ma	nuscript number (if known):		
rela par to t	ated to the content of your ties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.	
	e following questions apply nuscript only.	to the author's relationsh	nips/activities/interests as they relate to the current	
me In it	dication, even if that medi	cation is not mentioned in	e all relationships with manufacturers of antihypertensing the manuscript. The manuscript without time limit. For all other	
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		needed) Time frame: Since the initi	ial planning of the work	
	All support for the present	X None	ar planning of the work	
-	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time from a man	at 26 months	
,	Grants or contracts from	Time frame: pas	st 36 months	
'	any entity (if not indicated	XNone		

in item #1 above).

Royalties or licenses

Consulting fees

None

X__None

- 1		T	T
5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	•		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

I have no conflict of interests to declare.	
---	--

Please place an "X" next to the following statement to indicate your agreement:

Dat	e:October 12, 2021 _		
You	r Name:Natsumi Ma	tsuura	
Mai	nuscript Title:Prognostic sigr	nificance of postoperative	longitudinal change of serum carcinoembryonic antigen level
in p	atients with stage I lung ade	enocarcinoma completely i	resected by single-port VATS: a retrospective study
Maı	nuscript number (if known):		
rela part to t rela The	ted to the content of your naties whose interests may be ransparency and does not not tionship/activity/interest, it following questions apply to	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current
maı	nuscript only.		
med In it	dication, even if that medica	ntion is not mentioned in the port for the work reported	all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other items,
		None all autition with	Superifications/Community
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	satuatis,
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
2	in item #1 above).	V N	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
0	Dankisia skiana ana Daka	V N	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Descipt of anythment	V Name	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

I have no conflict of interests to declare.		
I have no conflict of interests to declare.		

Please place an "X" next to the following statement to indicate your agreement:

Dat	e:O	ct. 12, 2021	
You	r Name:Ji	n Yong Jeong	
anti stud	gen level in patients with st	age I lung adenocarcinom	erative longitudinal change of serum carcinoembryonic a completely resected by single-port VATS: a retrospective
rela part to t	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply to	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
med In it	lication, even if that medica	tion is not mentioned in t	all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	X None	

any entity (if not indicated

_None

__None

in item #1 above).

Royalties or licenses

Consulting fees

-		1	T
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

I have no conflict of interests to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:	Oct. 12, 2021	
Your Name:	Bo Su	
Manuscript Title:	Prognostic significanc	e of postoperative longitudinal change of serum carcinoembryonic
antigen level in patie	ents with stage I lung ade	nocarcinoma completely resected by single-port VATS: a retrospective
study		
Manuscript number	(if known):	
	• • •	disclose all relationships/activities/interests listed below that are elated" means any relation with for-profit or not-for-profit third

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	XNone	

- 1		T	T
5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	•		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

I have no conflict of interests to declare.	
---	--

Please place an "X" next to the following statement to indicate your agreement:

Dat	e:Oct	:. 12. 2021	
		Xiao Zhou	
Mai	nuscript Title:Progn	ostic significance of posto	perative longitudinal change of serum carcinoembryonic
	-		ma completely resected by single-port VATS : a retrospective
stuc	dy		
Mai	nuscript number (if known):	
rela part to t	ted to the content of your ties whose interests may b	manuscript. "Related" mo e affected by the content necessarily indicate a bias	Ill relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.
	following questions apply nuscript only.	to the author's relationsh	nips/activities/interests as they relate to the current
to t med In it	he epidemiology of hypert dication, even if that medic	ension, you should declar cation is not mentioned in port for the work report	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initi	
	All aumout for the present		al planning of the work
	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months

Grants or contracts from

in item #1 above).

Royalties or licenses

Consulting fees

3

any entity (if not indicated

X__None

X__None

None

- 1		T	T
5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	XNone	
-	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

I have no conflict of interests to declare.	
---	--

Please place an "X" next to the following statement to indicate your agreement: